ABSTRACT
PURPOSE: The teratoid histologic variant of Wilms' tumor is rare, with only 15 prior reported cases. We review these and report an additional case in which a cytogenetic abnormality was identified that has not previously been reported in a teratoid Wilms' tumor. MATERIALS AND METHODS: A medline search revealed 15 previously reported cases of the teratoid variant of Wilms' tumor. We summarized the characteristics of these cases with attention to radiologic appearance, stage, laterality, histology, response to chemotherapy and outcomes. RESULTS: Characteristic radiologic features suggesting teratoid Wilms' tumor were calcific densities and stippling, or areas of attenuation indicating adipose tissue. The majority of teratoid Wilms' tumor patients had a high tumor stage at presentation (50% stage III or greater). The incidence of bilateral tumors was 38%. Chemotherapy was administered in nine cases and in only one (11%) was there a cytoreductive response. Four deaths (25%) occurred amongst these patients. CONCLUSIONS: Teratoid Wilms' tumors appear to present with a high stage, increased incidence of bilaterality and have a high mortality rate. Treatment strategies should focus on total surgical extirpation, including metastatic sites when feasible, due to this entity's limited response to chemotherapy.
ABSTRACT
Between 1977 and 1991, the Children's Cancer Group and the National Cancer Institute conducted three trials of very high-dose methotrexate (33.6 g/m2; VHD-MTX) in place of cranial radiation (CRT) as central nervous system (CNS) preventive therapy, and assessed efficacy, acute toxicity and long-term neurocognitive outcome. CCG-191P compared VHD-MTX to CRT plus intrathecal methotrexate (IT-MTX) in 181 patients and demonstrated equivalent survival. However, patients treated with CRT had poorer performance on neurocognitive testing over time. CCG-134P evaluated the addition of intensified systemic and intrathecal therapy to VHD-MTX in 128 patients with high-risk acute lymphoblastic leukemia (ALL) and demonstrated reduced CNS relapse compared to the CCG-191P trial, but equivalent survival. CCG-144P compared VHD-MTX to IT-MTX alone in 175 patients with average-risk ALL and demonstrated equivalent survival. VHD-MTX was associated with significant toxicities, particularly neutropenia, transient hepatic dysfunction and sepsis. VHD-MTX achieved similar survival to other CNS-directed therapies without the long-term impact on intelligence, but with substantial acute toxicities.
Subject(s)
Central Nervous System Neoplasms/prevention & control , Methotrexate/therapeutic use , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Adolescent , Adult , Child , Child, Preschool , Cognition/drug effects , Female , Humans , Infant , Male , Pilot Projects , Risk , Treatment OutcomeABSTRACT
To evaluate t(2;5) and its variants, we studied 21 pediatric cases of anaplastic lymphoma kinase (ALK)+ anaplastic large cell lymphoma (ALCL) by using immunohistochemical staining, fluorescence in situ hybridization, cytogenetics, and reverse transcriptase-polymerase chain reaction. Results showed 7 (33%) cases with t(2;5), 6 (29%) with variant gene rearrangements, 7 (33%) with uncharacterized rearrangements, and 1 with ALK protein expression but no ALK rearrangement. Among 6 variant gene rearrangements, 1 had TPM4-ALK/t(2;19)(p23;p13) and 2 had inv(2) with the breakpoint proximate to ATIC-ALK and an unknown partner gene separately. The genetic features of the remaining 3 cases were as follows: ins(8;2) with an unknown partner gene; conversion from ALK- at diagnosis to ALK+ at recurrence with unspecified gene rearrangement; complex karyotype without involvement of 2p23, suggesting a cryptic translocation. Concordance between different laboratory results varied from 47% to 81%. These data suggest that ALK variants are not uncommon and underscore the necessity of integrating immunohistochemical, cytogenetic, and molecular genetic approaches to detect, characterize, and confirm t(2;5) and its variant translocations.
Subject(s)
Gene Rearrangement/genetics , Lymphoma, Large B-Cell, Diffuse/genetics , Lymphoma, Large B-Cell, Diffuse/metabolism , Protein-Tyrosine Kinases/genetics , Protein-Tyrosine Kinases/metabolism , Adolescent , Adult , Anaplastic Lymphoma Kinase , Child , Child, Preschool , Chromosome Aberrations , Female , Humans , Immunohistochemistry , Immunophenotyping , In Situ Hybridization, Fluorescence , Male , Receptor Protein-Tyrosine Kinases , Reproducibility of Results , Retrospective Studies , Reverse Transcriptase Polymerase Chain Reaction , Translocation, GeneticSubject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Thymoma/drug therapy , Thymus Neoplasms/drug therapy , Thymus Neoplasms/pathology , Tumor Lysis Syndrome/etiology , Adolescent , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biopsy, Needle , Combined Modality Therapy , Follow-Up Studies , Humans , Immunohistochemistry , Magnetic Resonance Imaging , Male , Risk Assessment , Thoracotomy/methods , Thymoma/pathology , Thymoma/surgery , Thymus Neoplasms/surgery , Tumor Lysis Syndrome/therapyABSTRACT
BACKGROUND: Renal cell carcinoma (RCC) is rare in children and comprises only 1-3% of all pediatric primary renal tumors. Recently, several case reports have described RCC developing in patients previously treated for advanced stage neuroblastoma (NB). METHODS AND RESULTS: Our experience with four patients treated for advanced stage NB during early childhood who developed RCC later in life are added to 14 others in the literature. CONCLUSION: These patients and our review of the literature suggest an association between RCC and NB that warrants further study.
Subject(s)
Carcinoma, Renal Cell/diagnosis , Kidney Neoplasms/diagnosis , Neuroblastoma/pathology , Adolescent , Adult , Carcinoma, Renal Cell/pathology , Carcinoma, Renal Cell/therapy , Child , Child, Preschool , Female , Humans , Infant , Kidney Neoplasms/pathology , Kidney Neoplasms/therapy , Magnetic Resonance Imaging , Male , Neuroblastoma/therapy , Tomography, X-Ray ComputedABSTRACT
Primary spinal epidural Burkitt lymphoma, presenting with signs of spinal cord compression, is very uncommon in childhood. Previously reported pediatric cases with isolated epidural Burkitt lymphoma had a high mortality, and survivors usually suffered serious neurologic sequelae. The authors present a 13-year-old female with isolated epidural Burkitt lymphoma with favorable outcome, and review the pediatric literature.
Subject(s)
Burkitt Lymphoma/pathology , Epidural Neoplasms/pathology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Burkitt Lymphoma/drug therapy , Epidural Neoplasms/drug therapy , Epidural Space , Female , Humans , Infant , Spinal Cord Compression/diagnosisSubject(s)
Antineoplastic Agents, Phytogenic/adverse effects , Muscle Weakness/chemically induced , Neural Conduction/drug effects , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Vincristine/adverse effects , Antineoplastic Agents, Phytogenic/administration & dosage , Charcot-Marie-Tooth Disease/complications , Charcot-Marie-Tooth Disease/diagnosis , Child, Preschool , Diagnosis, Differential , Guillain-Barre Syndrome/complications , Guillain-Barre Syndrome/diagnosis , Humans , Male , Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis , Treatment Outcome , Vincristine/administration & dosageABSTRACT
CD44 is a ubiquitous multifunctional cell surface adhesion molecule family. High expression of the standard form, CD44s (CD44), and its variant form, CD44v6, has been reported to be associated with tumor dissemination in non-Hodgkin lymphoma. To evaluate the potential role of CD44 and/or CD44v6 in different entities of anaplastic large cell lymphoma (ALCL), 30 cases of systemic ALCL (sALCL; 20 cases) and primary cutaneous ALCL (cALCL; 10 cases) were compared for expression of CD44 and CD44v6 by immunohistochemical staining. Expression of CD44v6 also was analyzed with respect to expression of anaplastic lymphoma kinase (ALK) in sALCL. No difference of CD44 expression was noted between sALCL and cALCL In contrast, expression of CD44v6 was found in 18 (90%) of sALCL cases and in 5 (50%) of cALCL cases. There was no correlation between expression of CD44v6 and expression of ALK in sALCL. These results indicate that expression of CD44v6 rather than CD44 correlates with sALCL. Furthermore, these results suggest that CD44v6 and ALK may be independent predictors of risk for the systemic phenotype of ALCL.
